ES2037672T3 - Utilizacion de pteridinas y/o purinas o de un inhibidor de xantinoxidasa para la fabricacion de un medicamento para el tratamiento de enfermedades degenerativas de la retina condicionadas geneticamente. - Google Patents

Utilizacion de pteridinas y/o purinas o de un inhibidor de xantinoxidasa para la fabricacion de un medicamento para el tratamiento de enfermedades degenerativas de la retina condicionadas geneticamente.

Info

Publication number
ES2037672T3
ES2037672T3 ES198787102094T ES87102094T ES2037672T3 ES 2037672 T3 ES2037672 T3 ES 2037672T3 ES 198787102094 T ES198787102094 T ES 198787102094T ES 87102094 T ES87102094 T ES 87102094T ES 2037672 T3 ES2037672 T3 ES 2037672T3
Authority
ES
Spain
Prior art keywords
pteridines
treatment
xantinoxidase
purines
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787102094T
Other languages
English (en)
Inventor
Gertrud Prof. Dr. Cremer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharm Allergan GmbH
Original Assignee
Pharm Allergan GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharm Allergan GmbH filed Critical Pharm Allergan GmbH
Application granted granted Critical
Publication of ES2037672T3 publication Critical patent/ES2037672T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

UTILIZACION DE PTERIDINA Y/O PRECURSORES BIOQUIMICOS DE XANTINOXIDASA RETARDADA PARA EL TRATAMIENTO DE ENFERMEDADES DE RETINA DEGENERATIVAS ORIGINADAS GENETICAMENTE, ESPECIALMENTE RETINOPATIA PIGMENTOSA (RP) Y FABRICACION DE UN MEDICAMENTO CORRESPONDIENTE.
ES198787102094T 1987-02-13 1987-02-13 Utilizacion de pteridinas y/o purinas o de un inhibidor de xantinoxidasa para la fabricacion de un medicamento para el tratamiento de enfermedades degenerativas de la retina condicionadas geneticamente. Expired - Lifetime ES2037672T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP87102094A EP0278040B1 (de) 1987-02-13 1987-02-13 Verwendung von Pteridinen und/oder Purinen oder eines Xanthinoxidase-Hemmers zur Herstellung eines Arzneimittels zur Behandlung von genetisch bedingten degenerativen Netzhauterkrankungen

Publications (1)

Publication Number Publication Date
ES2037672T3 true ES2037672T3 (es) 1993-07-01

Family

ID=8196754

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787102094T Expired - Lifetime ES2037672T3 (es) 1987-02-13 1987-02-13 Utilizacion de pteridinas y/o purinas o de un inhibidor de xantinoxidasa para la fabricacion de un medicamento para el tratamiento de enfermedades degenerativas de la retina condicionadas geneticamente.

Country Status (6)

Country Link
US (1) US4943575A (es)
EP (1) EP0278040B1 (es)
JP (1) JPS63239222A (es)
AT (1) ATE66147T1 (es)
DE (1) DE3772193D1 (es)
ES (1) ES2037672T3 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1708690T3 (en) 2003-11-17 2016-11-07 Biomarin Pharm Inc TREATMENT OF PHENYLKETONURI WITH BH4
US8003126B2 (en) * 2004-11-17 2011-08-23 Biomarin Pharmaceutical Inc. Stable tablet formulation
US20090075992A1 (en) * 2005-01-07 2009-03-19 University Of Strathclyde Pteridine Derivatives as Nitric Oxide Synthase Activators
US20060194800A1 (en) * 2005-01-07 2006-08-31 University Of Strathclyde Pteridine derivatives as nitric oxide synthase activators
MX2008015266A (es) 2006-06-01 2009-02-10 Nobera Pharma Sl Uso del alopurinol para el tratamiento de la eritrodisestesia palmo-plantar.
EP2246057A1 (en) * 2009-04-29 2010-11-03 Nobera Pharma, S.L. Use of allopurinol for the treatment of hand foot skin reaction
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425346A (en) * 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
IE51421B1 (en) * 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
EP0059524A1 (en) * 1981-02-09 1982-09-08 Smith and Nephew Associated Companies p.l.c. Pharmaceutical composition containing aminopteridines or aminopyrimido(4,5-d)pyrimidines
JPS61194020A (ja) * 1985-02-22 1986-08-28 Dai Ichi Seiyaku Co Ltd 網膜症治療剤

Also Published As

Publication number Publication date
ATE66147T1 (de) 1991-08-15
EP0278040A1 (de) 1988-08-17
JPS63239222A (ja) 1988-10-05
US4943575A (en) 1990-07-24
DE3772193D1 (de) 1991-09-19
EP0278040B1 (de) 1991-08-14

Similar Documents

Publication Publication Date Title
AU4732989A (en) Pyrimidines and their pharmaceutical acceptable salts thereof, and their use as medicines
HK1004257A1 (en) Use of droloxifene in the treatment of bone diseases
AU591125B2 (en) Therapeutic nucleosides
GR3007790T3 (es)
GB9423911D0 (en) Therapeutic agents
ES2058592T3 (es) El uso de sustancias activas fisiologicamente para la fabricacion de medicamentos para enfermedades cerebrales y neuronales.
IL91796A0 (en) Pharmaceutical preparations comprising gamma-interferon
ES2059375T3 (es) Utilizacion del tetrahidrocortisol en la terapia del glaucoma.
ES2037672T3 (es) Utilizacion de pteridinas y/o purinas o de un inhibidor de xantinoxidasa para la fabricacion de un medicamento para el tratamiento de enfermedades degenerativas de la retina condicionadas geneticamente.
CA2163118A1 (en) Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use
DK393188D0 (da) Farmaceutisk praeparat til intranasal administrering
ES2055163T3 (es) Utilizacion del cofactor-enzima nadph para la preparacion de un medicamento asi como el medicamento preparado de este modo y procedimiento para su preparacion.
ES2111104T3 (es) Utilizacion de nadh y nadph para la fabricacion de un medicamento para el tratamiento de la enfermedad de alzheimer.
IE831386L (en) Pharmaceutical compositions based on xylosides and lyxosides¹of purine and pyrimidine bases
GB8822546D0 (en) Antiviral combinations
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
IT1245717B (it) Composto farmaceutico a base di un antocianidina per il trattamento di malattie oftalmiche
EP0373771A3 (en) New pharmaceutical uses for cystatins
IE870577L (en) Topical amide preparation
AU3934689A (en) New furylthiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
AU8209987A (en) Hypertension treatment using K+ channel activator and ace inhibitor agents
ES2059058T3 (es) Combinacion sinergica para uso oftalmico.
SE8503771D0 (sv) Novel pharmaceutical preparations
ES2037807T3 (es) Medicamentos que contienen en combinacion interferon y 1-desoxi-piperidinosas, procedimiento para su fabricacion y su aplicacion.
EP0454429A3 (en) Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 278040

Country of ref document: ES